Renal profile of chronic hepatitis C patients with sofosbuvir-based therapy

• Published in: Infection 2020-12, Vol.48 (6), p.913-922
• Main Authors: El-Sayed, Mohammad, Abdellatif, Zeinab, Elsharkawy, Aisha, El Kassas, Mohamed, Abd Elmoniem, Reham, Marzouk, Amaal, Fouad, Rabab, Esmat, Gamal, Abdel Alem, Shereen
• Format: Article
• Language: English
• Subjects: Antiviral drugs; Creatinine; Epidemiology; Epidermal growth factor receptors; Family Medicine; General Practice; Health services; Hepatitis; Hepatitis C; Infectious Diseases; Internal Medicine; Kidney diseases; Kidneys; Mathematical analysis; Medicine; Medicine & Public Health; Original Paper; Patients; Renal function; Ribavirin; Risk analysis; Risk factors; Therapy
• ISSN: 0300-8126; 1439-0973
• DOI: 10.1007/s15010-020-01505-5

Purpose The impact of SOF-based therapy on renal functions is quite controversial in clinical practice. Therefore, we aimed to evaluate the serial changes of renal indices during SOF-based therapy in CHC patients with normal kidney function or mild renal impairment. Methods We retrospectively reviewed all CHC patients who received different SOF-based regimens from January 2015 until December 2017, and presented with a baseline eGFR ≥ 30 ml/min/1.73m 2 . Patients who didn't achieve SVR, with missing creatinine or eGFR data, and patients with eGFR less than 30 ml/min/1.73m 2 at baseline were excluded. eGFR was calculated for each time of evaluation using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. Results A total of 1004 patients were finally included. The mean serum creatinine and eGFR levels varied between 0.84 mg/dl and 106.53 ml/min/1.73m 2 for baseline and 0.87 mg/dl and 104.24 ml/min/1.73m 2 for SVR12, respectively. The maximum increase of creatinine was 3.69 mg/dl and the maximum decrease of eGFR level was 83.30 ml/min/1.73m 2 during treatment. Moreover, 74.4% of treated patients stayed in the same eGFR category, 14.3% progressed to a higher eGFR category, and 11.3% had an improvement eGFR category at EOT and continued to SVR12. Age > 65 years, baseline eGFR, and ribavirin–containing regimens were independent risk factors of eGFR decline during and after SOF-based treatment. Conclusion SOF-based therapies seem to be safe in CHC patients with baseline normal or slightly impaired renal function.